4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immuneering Corporation (IMRX) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 55 employees. Its market capitalization is roughly $346 million. In the fiscal year ended 2025-12-31, IMRX reported $0M in revenue and ($56M) in net income.
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | — | $0M | $0M | $1M |
| Operating Income (EBIT) | ($59M) | ($64M) | ($58M) | ($52M) | — |
| Net Income | ($56M) | ($61M) | ($54M) | ($50M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($15M) | ($14M) | ($15M) | ($15M) | ($16M) | — |
| Net Income | ($14M) | ($12M) | ($15M) | ($14M) | ($15M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $232M | $53M | $103M | $122M | — |
| Total Liabilities | $14M | $11M | $12M | $12M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMRX viewer.
About TickerBase · Data methodology & sources